Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its innovative HIV treatments, is navigating a complex landscape of opportunities and challenges as it seeks to diversify its portfolio and secure long-term growth. With a market capitalization of $133.6 billion and impressive last twelve months revenue of $28.7 billion, Gilead maintains its position as a prominent player in the biotechnology industry. According to InvestingPro analysis, the company’s financial health score is rated as "GREAT," reflecting its strong operational foundation. With a strong foundation in antiviral therapies and an expanding oncology franchise, Gilead is positioning itself for the future while facing the looming loss of exclusivity for its blockbuster HIV drug Biktarvy.

Company Overview and Recent Performance

Gilead Sciences has established itself as a leader in the development of treatments for life-threatening illnesses, with a particular focus on HIV/AIDS, liver diseases, hematology/oncology, and inflammatory and respiratory conditions. The company’s stock has shown resilience, trading near $90 in late 2024, buoyed by successful clinical trials and strategic positioning in key therapeutic areas.

In the third quarter of 2024, Gilead demonstrated strong operational execution, with better-than-expected product sales driven by its HIV drug Biktarvy and COVID-19 treatment Veklury. This performance led the company to raise its full-year 2024 guidance by $650 million for product sales and $750 million for operating income. The company’s robust financial position is evidenced by its impressive 78.3% gross profit margin and strong cash flows that adequately cover interest payments. Want deeper insights? InvestingPro subscribers have access to over 30 additional financial metrics and exclusive analysis. Analysts now project total revenues of approximately $28.3 billion for 2024, with non-GAAP earnings per share estimated at $4.41.

HIV Treatment and PrEP Market

Gilead’s HIV franchise remains the cornerstone of its business, with Biktarvy leading the charge. However, the company is actively preparing for the post-Biktarvy era, as the drug is expected to lose exclusivity in 2033. A key component of Gilead’s strategy is the development of lenacapavir, a long-acting HIV treatment and prevention option.

Lenacapavir, slated for launch as a pre-exposure prophylaxis (PrEP) treatment in the summer of 2025, represents a significant opportunity for Gilead. The company aims to capture over 60% of the US market share for Descovy/lenacapavir by mid-2030 and achieve over 80% adherence for lenacapavir. Analysts project that lenacapavir could generate $118 million in PrEP revenues in 2025, potentially growing to over $5 billion at peak.

Gilead is targeting expansion of the US PrEP market to well over 1 million patients by the mid-2030s. This growth strategy includes efforts to increase both consumer awareness and prescriber engagement. The company plans to achieve approximately 75% coverage within the first six months of lenacapavir’s launch and around 90% at twelve months.

Oncology Portfolio and Pipeline

As Gilead looks to diversify beyond its core HIV business, the oncology franchise has emerged as a key growth driver. The company’s efforts in this space are led by Trodelvy and its cell therapy programs, including the promising anito-cel for relapsed/refractory multiple myeloma (RRMM).

Anito-cel has shown competitive efficacy in Phase 2 trials, with a 97% overall response rate and potentially improved safety profile compared to existing treatments. Gilead is targeting a 2026 launch for anito-cel and estimates the global CAR T market for multiple myeloma could reach $12 billion by 2030.

Despite these promising developments, Gilead faces challenges in its cell therapy franchise, with analysts noting competitive pressures that are expected to continue into 2025. The success of the oncology portfolio will be crucial for Gilead’s growth prospects, particularly as it seeks to offset potential revenue declines in its maturing HIV business.

Future Growth Drivers and Challenges

Gilead’s future growth hinges on several key factors. The company is focused on expanding its HIV treatment lifecycle management post-Biktarvy loss of exclusivity, leveraging lenacapavir for both treatment and prevention. In oncology, the success of Trodelvy and the development of cell therapies like anito-cel are critical for diversifying revenue streams.

However, Gilead faces challenges in maintaining its market position. The company must navigate a fragmented HIV treatment market and overcome hurdles in PrEP adoption. Additionally, the oncology space is highly competitive, and Gilead will need to demonstrate clear differentiation and clinical benefits to capture market share.

Bear Case

How will Gilead manage the impact of Biktarvy’s loss of exclusivity in 2033?

Biktarvy’s patent expiration in 2033 poses a significant risk to Gilead’s revenue stream. The company’s ability to transition patients to new treatments and maintain market share will be crucial. While Gilead has a track record of successful pre-loss of exclusivity market conversion, the HIV treatment landscape is becoming increasingly competitive. The company’s pipeline of new HIV treatments, including long-acting options, will need to demonstrate clear advantages to retain patients and attract new ones. There is a risk that these new treatments may not fully compensate for the potential revenue loss from Biktarvy, which could impact Gilead’s financial performance in the mid-2030s and beyond.

Can Gilead overcome the challenges in its cell therapy franchise?

Gilead’s cell therapy franchise, particularly in oncology, faces intense competition and operational challenges. The company has reported declines in this segment, with expectations of continued pressure into 2025. While anito-cel shows promise, it enters a market with established competitors like Carvykti. Gilead must demonstrate superior efficacy and safety profiles to gain significant market share. Additionally, the complex manufacturing and administration processes associated with cell therapies present logistical and cost challenges. If Gilead cannot overcome these hurdles and differentiate its offerings, it may struggle to achieve the projected growth in this critical segment of its portfolio.

Bull Case

How might lenacapavir’s potential in HIV treatment and prevention drive growth?

Lenacapavir represents a significant opportunity for Gilead to maintain its leadership in HIV treatment and prevention. As a long-acting agent, it addresses key challenges in patient adherence and could revolutionize the PrEP market. Gilead’s ambitious target of capturing over 60% US market share for Descovy/lenacapavir by mid-2030 suggests substantial revenue potential. The projected expansion of the US PrEP market to over 1 million patients by the mid-2030s provides a large addressable market. If Gilead can successfully execute its launch strategy and achieve high coverage rates, lenacapavir could become a multi-billion dollar product, potentially offsetting losses from Biktarvy’s patent expiration and driving long-term growth.

What is the growth potential of Gilead’s oncology portfolio?

Gilead’s oncology portfolio, led by Trodelvy and emerging cell therapies like anito-cel, presents a significant growth opportunity. The global CAR T market for multiple myeloma is estimated to reach $12 billion by 2030, and Gilead is positioning itself to capture a substantial share. Anito-cel’s promising efficacy and safety profile in RRMM could make it a preferred treatment option. If approved and launched in 2026 as targeted, it could become a $5 billion drug at peak. Furthermore, success in oncology would diversify Gilead’s revenue streams, reducing dependence on the HIV franchise. As the company continues to invest in and expand its oncology pipeline, it has the potential to become a major player in this high-growth therapeutic area, driving overall company growth and valuation.

SWOT Analysis

Strengths

• Strong leadership position in HIV treatment and prevention
• Robust HIV pipeline with long-acting agents like lenacapavir
• Growing oncology franchise with promising candidates like anito-cel
• Effective operational execution and cost management

Weaknesses

• Heavy reliance on HIV franchise, particularly Biktarvy
• Challenges in cell therapy segment with competitive pressures
• Declining hepatitis C virus (HCV) market

Opportunities

• Expansion of PrEP market with lenacapavir launch
• Growth in oncology through Trodelvy and cell therapies
• Potential for multiple new product launches in coming years

Threats

• Biktarvy loss of exclusivity in 2033
• Increasing competition in HIV and oncology markets
• Potential pricing pressures and healthcare policy changes
• Risks associated with clinical trial outcomes and regulatory approvals

Analysts Targets

• BMO Capital Markets (March 19, 2025): $115.00 (Outperform)
• BMO Capital Markets (January 29, 2025): $110.00 (Outperform)
• Piper Sandler (December 12, 2024): $105.00 (Overweight)
• Cantor Fitzgerald (December 11, 2024): $80.00 (Neutral)
• RBC Capital Markets (December 11, 2024): $84.00 (Sector Perform)
• BMO Capital Markets (December 10, 2024): $102.00 (Outperform)
• RBC Capital Markets (November 18, 2024): $84.00 (Sector Perform)
• Cantor Fitzgerald (November 7, 2024): $80.00 (Neutral)
• RBC Capital Markets (November 7, 2024): $81.00 (Sector Perform)
• Barclays (LON:BARC) (November 7, 2024): $95.00 (Equal Weight)
• RBC Capital Markets (October 29, 2024): $75.00 (Sector Perform)

Gilead Sciences faces a critical juncture as it navigates the transition from its dominant HIV franchise to a more diversified portfolio. The success of its HIV lifecycle management strategy, coupled with the growth of its oncology business, will be key determinants of the company’s future performance. While challenges remain, particularly with the looming loss of exclusivity for Biktarvy, Gilead’s strong pipeline and strategic initiatives position it for potential long-term success in the evolving biopharmaceutical landscape.

This analysis is based on information available up to May 27, 2025, and market conditions may have changed since then. Based on InvestingPro’s comprehensive Fair Value analysis, Gilead is currently trading near its Fair Value, with a P/E ratio of 22.5x and a price-to-book ratio of 7x. For exclusive access to detailed valuation metrics, real-time alerts, and professional-grade analysis tools, explore InvestingPro’s complete suite of investment research solutions.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on GILD. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore GILD’s full potential at InvestingPro.

Should you invest in GILD right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if GILD is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate GILD further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if GILD appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.